The New Gold Trade Dominating on Wall Street
Wall Street has been making headlines lately for piling into gold. According to Dr. David Eifrig, the gold bull run is just getting started. He says you should move your money to his No. 1 gold stock immediately (not a miner or ETF but it has 1,000% upside potential.)
Shares Stats
| Shares Outstanding | 96,270,000 |
| Shares Float | 89,650,000 |
| Shares Short | 7,140,000 |
| Insider Holdings | 313% |
| Institution Holdings | 100.80% |
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
General
| Name | Ultragenyx Pharmaceutical Inc |
| Ticker | RARE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 1,294 |
Highlights
| Analyst Target | 83.65 |
| Market Cap | 3,178,000,000 |
| PEG Ratio | -0.24 |
| EBITDA | -508,700,992 |
Financials
| Curr Year EPS Estimate | -5.72 |
| Next Quarter EPS Estimate | -1.11 |
| Profit Margin | -91.95% |
| Operating Margin | -86.27 |
| Return on Assets | -0.25 |
| Return on Equity | -3.13 |
| Revenue | 630.6M |
| Earnings Per Share | -5.93 |
| Revenue Per Share | 6.46 |
| Gross Profit | -163,816,000 |
| Quarterly Revenue Growth | 0.15 |
Valuation
| Price/Sales (Trailing 12 Mt.) | 5.13 |
| Price/Book (Most Recent Quarter) | 353.09 |
Earnings
Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms
The new ETFs offer 2x exposure to Bloom Energy, Celestica, NANO Nuclear Energy, and Synopsys—each linked to America's expanding AI infrastructure.
AutoZone's Domestic 'Do It For Me' Business Driving Market Share Gains
Goldman Sachs upgrades AutoZone to Buy after recent sell-off, highlighting double-digit domestic DIFM growth, share gains, and long-term EPS upside through FY28.
A Low-Profile Memecoin Is Quietly Gaining Serious Momentum - Ad
While everyone's watching the big-name coins, a lesser-known memecoin is gathering speed. With unique utility, a growing user base, and strong chart signals, our research team believes this could be a breakout waiting to happen.
Home Depot Could Hammer Out Gains With Pro Expansion, Analyst Says
Bank of America expects Home Depot's Q3 earnings to show 1.3% sales increase. Analysts maintain Buy rating and $450 price forecast.
Is Floor & Decor Quietly Positioning For A 2026 Housing Upswing?
Goldman Sachs upgrades Floor & Decor Holdings to Neutral, citing potential market-share gains and improved housing conditions in 2026.
Another Gold High? Here's the Move Wall Street Is Missing ... - Ad
Gold just surged past $4,200, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.
Why Airlines May Hold Pricing Power Into 2026 Even After Shutdown Disruptions
BofA Securities says US airlines are strong despite shutdown, with core demand drivers and capacity discipline supporting positive outlook.
Nasdaq 100 Faces Worst November Since 2008 As AI Boom Hits A Wall
The Nasdaq 100 is breaking its bullish November streak as AI infrastructure bottlenecks, led by CoreWeave, shake up 2025 tech market performance.
America's Next Security Revolution Has Begun - Ad
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
Marjorie Taylor Greene Buys 6 Stocks: Buffett, Health Care — And This Magnificent 7 Stock
Marjorie Taylor Greene discloses buying more stocks in October. Here's a look at what she added to her portfolio.
Buy This Stock Tomorrow? - Ad
A renowned former hedge fund manager - friends to some of the biggest investors in the world - just released a new list of his favorite AI stocks... and not a single Magnificent 7 name made the cut. Instead, an AI stock you've likely never heard of just flagged as "near-perfect" in his new investing scoring system.
Why a Visa-Mastercard legal settlement could lead to your rewards credit card getting declined
NEW YORK (AP) — Visa and Mastercard have proposed a settlement in their long-running legal dispute with merchants and retailers over how much they charge merchants to accept their cards.
Jury awards $28M to family of a United Nations consultant killed in Boeing 737 Max crash in Ethiopia
A federal court jury has awarded more than $28 million to the family of a woman who died in the crash of a Boeing 737 Max jetliner in Ethiopia more than six years ago.
The K7 Is Changing the Economics of Security - Ad
$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.
Trump administration and private investors sign off on $1.4 billion deal with rare earth startups
WASHINGTON (AP) — The Trump administration and private investors are partnering with two rare earth startups in a $1.4 billion deal to scale up the nation's access to materials and technology that is crucial for producing an array of high-tech goods and military equipment.
From beaches to ski slopes, photos show how cameras keep watch all over China
BEIJING, China (AP) —
After 50 Years of Chemo, One Biotech Could Lead the Next Cancer Breakthrough - Ad
For decades, toxic chemotherapy defined cancer care. This biotech's innovative approach could finally change that. With early results showing precision without poison, this story is one investors will want to see early.
Ford Expedition vs GMC Yukon, an Edmunds big SUV comparison
Let’s say you need a vehicle with room for more than five passengers, a large cargo area, and the ability to pull a heavy trailer. A full-size three-row SUV should work well, but which one? The most significant news this year is the redesigned . Ford has given its biggest SUV a complete makeover with a more upscale interior, new technology features and a novel split-opening tailgate.
Jim Cramer: Chipotle Is 'Too Expensive,' Buy This Plane Maker
On "Mad Money," Cramer discusses Henry Schein, Bloom Energy, Tyler Technologies, Boeing and Chipotle Mexican Grill.
This Overlooked Memecoin Is Showing Early Breakout Signals - Ad
We've been tracking one small memecoin that checks all the boxes: strong on-chain signals, real traction, and an entry point that could offer serious upside. It's not on many radars yet-but that could change fast.
Michael Caine and Matthew McConaughey partner with ElevenLabs for AI voice cloning
NEW YORK (AP) — Oscar-winning actors Michael Caine and Matthew McConaughey have made deals with voice-cloning company ElevenLabs that will allow its artificial intelligence technology to replicate their voices.
China's Singles' Day online shopping bonanza's sales slow as shoppers opt for more affordable deals
BANGKOK (AP) — Sales during China's largest online shopping festival, Singles' Day, jumped almost 18% from a year earlier but the pace of growth slowed as bargain hunters opted for more affordable deals.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit before November 18's bombshell.
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement.
Tesla's First Semi Vehicle Customer After Full Production Launch Is….Tesla?
Tesla Semi is one of several vehicles set for full-scale production in 2026 from Tesla. Here's the company's first major customer.
Why Wall Street Is Piling Into the "Debasement Trade" - Ad
Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.
FDA says drugmakers have recalled a blood pressure medicine tainted with a cancer-causing chemical
The U.S. Food and Drug Administration says drugmakers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical.
Trump no-show at big Asian economic forum may risk US reputation in region
GYEONGJU, South Korea (AP) — A hot mike caught U.S. President Donald Trump saying that his much-anticipated meeting Thursday , meant to settle the most important trade relationship in the world, would be “three, four hours” and he would then fly back to Washington.
The New Gold Trade Dominating on Wall Street - Ad
Wall Street has been making headlines lately for piling into gold. According to Dr. David Eifrig, the gold bull run is just getting started. He says you should move your money to his No. 1 gold stock immediately (not a miner or ETF but it has 1,000% upside potential.)
Court Blocks Trump's SNAP Reductions, But Stricter Eligibility Rules Begin
New work requirements for SNAP begin Saturday, but benefits may not be issued through November due to the government shutdown.
Dave Ramsey Reveals Why Millionaires Crush Mortgages Early
Dave Ramsey advises buying a home with cash, citing his firm's survey of millionaires who often retire their mortgages in about 10 years.
A Low-Profile Memecoin Is Quietly Gaining Serious Momentum - Ad
While everyone's watching the big-name coins, a lesser-known memecoin is gathering speed. With unique utility, a growing user base, and strong chart signals, our research team believes this could be a breakout waiting to happen.
Meta, Alphabet, Chipotle, Microsoft And Starbucks: Why These 5 Stocks Are On Investors' Radars Today
Major stock indexes traded mixed on Wednesday, with the Dow Jones Industrial Average slipping nearly 0.2% to 47,632 and the S&P 500 holding steady at 6,890.59.
Nearly 8 Million Shiba Inu Vanish After First SHIB ETF Filing Shakes Market
Nearly 8 million Shiba Inu (CRYPTO: SHIB) tokens have been incinerated following the inaugural filing of a Shiba Inu ETF, rekindling interest in the popular meme token.
Another Gold High? Here's the Move Wall Street Is Missing ... - Ad
Gold just surged past $4,200, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.
2 Federal Reserve officials oppose an interest rate cut in December
WASHINGTON (AP) — Two Federal Reserve officials expressed opposition Wednesday to another interest rate cut at the central bank's next meeting in December, the outlook for the Fed's next steps.
Sean Duffy Backs Trump's $10K Bonus, Urges Air Traffic Controllers' Return, Promises 70% Pay 'Within 48 Hours' Of Government Reopening
Sean Duffy urges air traffic controllers to return to work and reassures them of receiving 70% pay within 24-48 hours.
America's Next Security Revolution Has Begun - Ad
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
Toyota Fuels US Workforce With $14 Billion Battery Plant
Toyota starts U.S. battery production, unveils $10B extra investment and a $14B North Carolina hub slated for 5,100 jobs.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.